Case 32-2007: A 62-year-old woman with a second breast cancer

New England Journal of Medicine

Volumn 357, Issue 16, 2007, Pages 1640-1648

  Winer, Eric P ^a,b   Harris, Jay R ^a,b   Smith, Barbara L ^b,c   D'Alessandro, Helen Anne ^b,c   Brachtel, Elena F ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALENDRONIC ACID; AMFEBUTAMONE; ANTHRACYCLINE; AROMATASE INHIBITOR; ATORVASTATIN; CALCIUM CARBONATE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ELECTROLYTE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GADOLINIUM; IMIQUIMOD; LEVOTHYROXINE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BREAST BIOPSY; BREAST CANCER; BREAST DUCT; CALCIFICATION; CASE REPORT; CLINICAL TRIAL; ELECTROLYTE BLOOD LEVEL; FAMILY HISTORY; FEMALE; FIBROCYSTIC BREAST DISEASE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; KIDNEY FUNCTION TEST; LIVER FUNCTION; LYMPH VESSEL; MAMMOGRAPHY; MASTECTOMY; MENARCHE; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE; NULLIPARA; OVARY CYST; PATHOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT REFUSAL; TUMOR CELL; VULVA CARCINOMA; BREAST DISEASE; BREAST TUMOR; CALCINOSIS; CANCER INVASION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; RADIOGRAPHY; SECOND CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST DISEASES; BREAST NEOPLASMS; CALCINOSIS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, SECOND PRIMARY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 35348960906     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc079026     Document Type: Article

References (36)

1. Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-9.
2. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-7.
3. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374-81.
4. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4:Suppl 3:S1-S24.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
6. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-607.
7. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
8. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
9. Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
10. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994;73:643-51.
11. Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 1993;11:1545-52.
12. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002;158:220-35. [Erratum, Radiat Res 2002; 158:666.]
13. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
15. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485-92.
16. Chang JC, Hilsenbeck SG. Prognostic and predictive markers. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds: Diseases of the breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004:675-96.
17. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
18. Shen Y, Yan Y, Inoue LYT, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-203.
19. 0) breast carcinoma. J Clin Oncol 1989;7:355-66.
20. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-7.
21. Adjuvant! Online: decision making tools for health care professionals. (Accessed September 21, 2007, at http://www.adjuvantonline.com.)
22. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-25.
23. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
24. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006;24:3019-25.
25. Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 2001;27:335-7.
26. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471-9.
27. Albain K, Barlow W, O'Malley F, et al. Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (S8814). Breast Cancer Res Treat 2005;90:195. abstract.
28. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
29. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001;30:135-42. [Errata, J Natl Cancer Inst 2002;94:866, J Natl Cancer Inst Monogr 2003;31:131.]
30. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7. [Erratum, J Clin Oncol 2007;25:1819.]
31. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
33. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
34. Slamon D, Eiermann W, Robert N, et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2 positive early breast cancer patients: BCIRG 006 study. In: Program and abstracts of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 7-10, 2005. abstract.
35. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
36. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophasphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-over-expressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-9.